NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$135.2m

NGM Biopharmaceuticals Past Earnings Performance

Past criteria checks 0/6

NGM Biopharmaceuticals's earnings have been declining at an average annual rate of -35.7%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 26.1% per year.

Key information

-35.7%

Earnings growth rate

-26.0%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-26.1%
Return on equity-95.8%
Net Margin-3,223.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09
Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17
NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20
We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Mar 02
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Jan 26
Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

NGM Bio gives update on 2021 plans and data timeline

Jan 12

NGM Bio prices $125M share offering

Jan 06

NGM Biopharmaceuticals proposes $100M public offering

Jan 04

Revenue & Expenses Breakdown
Beta

How NGM Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:NGM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 234-142370
30 Sep 2322-151390
30 Jun 2330-17041-15
31 Mar 2337-178411
31 Dec 2255-163410
30 Sep 2258-153400
30 Jun 2269-1353980
31 Mar 2277-125391
31 Dec 2178-120370
30 Sep 2177-121350
30 Jun 2182-122320
31 Mar 2185-111294
31 Dec 2087-102270
30 Sep 2099-90260
30 Jun 2097-72250
31 Mar 20102-54250
31 Dec 19104-43240
30 Sep 19120-13220
30 Jun 19119-9220
31 Mar 19116-5190
31 Dec 181090170
30 Sep 1881-17160
30 Jun 1880-12150
31 Mar 1877-13150
31 Dec 1777-14150
31 Dec 1686-7120

Quality Earnings: NGM is currently unprofitable.

Growing Profit Margin: NGM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NGM is unprofitable, and losses have increased over the past 5 years at a rate of 35.7% per year.

Accelerating Growth: Unable to compare NGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NGM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: NGM has a negative Return on Equity (-95.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.